Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2036-2041

  Wanebo, H J ^a   Lee, J ^b   Burtness, B A ^c   Ridge, J A ^c   Ghebremichael, M ^b   Spencer, S A ^d   Psyrri, D ^e   Pectasides, E ^e   Rimm, D ^e   Rosen, F R ^f   Hancock, M R ^g   Tolba, K A ^h   Forastiere, A A ⁱ  

^a Landmark Medical Center   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e YALE UNIVERSITY   (United States)

^f Jr Hospital of Cook County

^g Porter Memorial Hospital   (United States)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cetuximab; chemoradiation; head neck; induction chemotherapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; MONOCLONAL ANTIBODY; PACLITAXEL;

ADULT; ADVERSE DRUG REACTION; AGED; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CARBOPLATIN; CETUXIMAB; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPITHELIAL CELLS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 84964314390     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu248     Document Type: Article

References (15)

1. Forastiere, A.A., Adelstein, D.J., Manola, J., Induction chemotherapy meta-analysis in head and neck cancer: right answer, wrong question. J Clin Oncol 31 (2013), 2844–2846.
2. Wanebo, H.J., Chougule, P., Ready, N., et al. Preoperative chemotherapy with paclitaxel and carboplatin and radiation achieves high rates of local regional control. Proc ASCO, 20, 2001 abstr 937.
3. Ready, N., Chougule, P., Nadeen, H., et al. Induction weekly paclitaxel carboplatin followed by concurrent paclitaxel, carboplatin and radiotherapy in advanced head and neck squamous cancers. Proc ASCO, 21, 2002 abstr 943.
4. Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
5. Cox, D.R., Snell, E.J., Analysis of Binary Data. 2nd Edition, 1989, Chapman and Hall, London.
6. Anderson, J.R., Cain, K.C., Gelber, R.D., et al. Analysis and interpretation of the comparison of survival by treatment outcome variables in Cancer Clinical Trials. Cancer Treat Rep 69 (1985), 1139–1144.
7. Camp, R.L., Chung, G.G., Rim, D.L., Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8 (2002), 1323–1327.
8. Weinberger, P.M., Ziwei, Y., Haffty, B.G., et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24 (2006), 736–747.
9. Kies, M.S., Holsinger, F.C., Lee, J., et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a Phase II prospective trial. J Clin Oncol 28 (2010), 8–14.
10. Argiris, A.E., Gibson, M.K., Heron, D.E., et al. Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation, P and E in locally advanced head and neck cancer. J Clin Oncol 28 (2010), 5294–5300.
11. Ang, K.K., Harris, J., Wheeler, R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363 (2010), 24–35.
12. Gillison, M.L., Zhang, Q., Jordan, R., et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30 (2012), 2102–2111.
13. Ang, K.K., Berkey, B.A., Tu, X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002), 7350–7356.
14. Psyrri, A., Yu, Z., Weinberger, P.M., Sasaki, C., et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11 (2005), 5856–5862.
15. Dittmann, K., Mayer, C., Fehrenbacher, B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280 (2005), 31182–31189.